For People with Diabetes, Starting an SGLT2 Inhibitor Could Lower Gout Risk
June 2nd 2023An analysis of more than 20,000 people with type 2 diabetes suggests initiating therapy with an SGLT2 inhibitor, as a second-line treatment to metformin, was associated with a lower risk of developing gout relative to other second-line therapies.
Pegloticase Use and Quality of Life in Uncontrolled Gout, with Brian LaMoreaux, MD
June 1st 2023Brian LaMoreaux, MD, discusses data from an analysis of the MIRROR trial examining the impact of pegloticase plus methotrexate on patient-reported outcomes and quality of life measures among patients with uncontrolled gout.
Nick Stucky, MD, Phd: Implications for Media Influence on Minoxidil Prescribing Rates
During this interview segment, Stucky continued on his team's findings on a newspaper article’s association with increased prescribing rates of oral minoxidil, explaining the study’s limitations and implications.
Ursula Schmidt-Erfurth, MD: Therapeutic Effect of Pegcetacoplan on GA Disease Activity
May 3rd 2023At ARVO 2023, Schmidt-Erfurth discusses new insights regarding disease activity in GA, observing reductions in both RPE and photoreceptor degeneration after intravitreal pegcetacoplan therapy in the OAKS and DERBY trials.
Andres Emanuelli, MD: Analysis of the Port Delivery System in the Phase 3 Pavilion Trial
May 3rd 2023At ARVO 2023, Emanuelli discusses the primary analysis results of the phase 3 Pavilion trial evaluating the PDS with ranibizumab in patients with diabetic retinopathy without center-involved diabetic macular edema.
Carl Danzig, MD: Analysis of GATHER Trials Connects GA Growth with Vision Loss
April 24th 2023In an interview at ARVO 2023, Danzig discusses the post-hoc analysis from the GATHER trials, showing that a reduced rate of vision loss in patients receiving avacincaptad pegol was correlated with reduced GA growth.
Caroline Baumal, MD: Marking a New Treatment Era for GA with Pegcetacoplan
April 24th 2023At ARVO 2023, Caroline Baumal, MD, chief medical officer of Apellis Pharmaceuticals, discussed new phase 3 functional analyses of pegcetacoplan injection, the future of the GA treatment landscape, and the next unmet need in ophthalmology.
New Insight: A Look at Avacincaptad Pegol with Pravin Dugel, MD
April 23rd 2023As part of our ARVO 2023 coverage, Dr. Sheth sat down with Pravin Dugel, MD, President of Iveric Bio to discuss avacincaptad pegol for geographic atrophy and a look back at Dr. Dugel's career and his transition into industry.